-
Recent Posts
Archives
- June 2019
- May 2018
- January 2018
- September 2017
- July 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- March 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- September 2013
- August 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
Categories
Blogroll
Monthly Archives: April 2014
An Update on Masochism
Since NIR’s post on ‘Those who fail to learn from obscenity are condemned to repeat it’, there has been some movement regarding both the overtures made by Valeant to Allergan, and Pfizer to AstraZeneca. 1) Allergan appears to be casting … Continue reading
Posted in Uncategorized
Leave a comment
Those Who Fail to Learn from Obscenity are Condemned to Repeat It
As May approaches, the ‘Street’ has perked up at the news and rumor, respectively, of two takeover aspirations: Valeant (with Pershing Square Capital) seeking to buy Allergan for $45.6 billion, Pfizer reportedly considering an offer of $101 billion for Astra … Continue reading
The Porcine Prerogative: A Perilous Precedent
While not falling within the CNS arena per se, the consequences of Gilead Pharma‘s decision to platinum-price Sovaldi for Hepatitis C, to the tune of $84,000 per three month treatment cycle in the US, eventually will permeate health care in … Continue reading
